SCHEMBL6049205

SCHEMBL6049205

CCOC(=O)c1ccccc1Oc1ccc(SC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.54
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 7/20 0.48
HTR2A P28223 1/20 0.48
SLC6A4 P31645 1/20 0.48
KCNH2 Q12809 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALK Q9UM73 1/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4397330 0.85 TSHR (0.61) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL538560 0.85 SMN1; SMN2 (0.68) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL27831715 0.84 TSHR (0.59) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL10953526 0.83 TSHR (0.57) TSHRSMN1; SMN2ALDH1A1SLC6A4HSD17B10
SCHEMBL28160008 0.83 ALDH1A1 (0.58) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL11424711 0.83 TSHR (0.57) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL28974979 0.82 TSHR (0.74) TSHRSMN1; SMN2ALDH1A1HSD17B10MAPT
SCHEMBL6049187 0.81 HTT (0.54) TSHRSMN1; SMN2ALDH1A1HTR2ASLC6A4
SCHEMBL18979007 0.81 SMN1; SMN2 (0.55) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1
SCHEMBL27254978 0.80 TSHR (0.57) TSHRSMN1; SMN2ALDH1A1HSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 TSHR 188/4885SMN1; SMN2 3041/4885ALDH1A1 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.